News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|November 18, 2020

Sharing the Results: ALKS 3831

Author(s)Adam Simmons, MPH

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Adam Simmons, MPH, shares results and insights from the Enlightened II study for Alkermes' drug, ALKS 3831.

To read more about ALKS 3831, see FDA Advisory Committee Votes in Favor of ALKS 3831.

Mr Simmons is the Director of Clinical Program Management at Alkermes.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, MD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, MD

ByMaciej Wieczorek, MD

October 27th 2025

catatonia

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

ByErica Taylor, MD, MPH,Drew Cumming, MD,James A. Bourgeois, OD, MD

October 24th 2025

blood test

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

October 23rd 2025

GLP1 semaglutide psychiatric disorders

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

ByJessica Walters

October 23rd 2025

psychiatry synchronicity serendipity

When Symptoms Are Not Necessarily Signs of Illness: Rethinking Synchronicity in Psychiatry

ByBernard Beitman, MD

October 23rd 2025

Latest CME

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Positive FDA Meeting for Abuse Deterrent Fentanyl Patch

Positive Phase 3 Results: CTx-1301 for the Treatment of Pediatric ADHD

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

Trick or Treat: Fiddling While Rome Burns or Playing a Violin of Hope?

The Dangers of Conversion Therapy: What Chiles v Salazar Could Mean for LGBTQ+ Youth

© 2025 MJH Life Sciences^®

All rights reserved.